InvestorsHub Logo
Followers 16
Posts 755
Boards Moderated 0
Alias Born 05/13/2016

Re: None

Tuesday, 08/08/2023 10:48:15 AM

Tuesday, August 08, 2023 10:48:15 AM

Post# of 550
Piper Sandler analyst Jason Bednar upgraded Novocure to Overweight from Neutral with an unchanged price target of $45. The "overwhelming pressure" on the shares has pushed the stock to levels where the risk/reward is "simply too attractive to remain on the sidelines" ahead of the soon-to-be-released Phase 3 data in recurrent ovarian cancer, the analyst tells investors in a research note. The firm sees "reasons to be upbeat" on INNOVATE-3 data and likes the potential for shares to move higher from current levels.
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NVCR News